Novo Nordisk reports 25% weight loss for CagriSema in women

Key points

• CagriSema, a combination of semaglutide and cagrilintide, showed 25% average weight loss in women at 68 weeks in a new analysis of roughly 2,300 participants.
• The drug targets the amylin pathway, a hormone that regulates hunger, aiming to improve upon the efficacy of GLP-1 drugs like Wegovy and Ozempic.
• Weight loss varied by menopausal status: 26.7% for premenopausal, 24.8% for perimenopausal, and 23.1% for postmenopausal women, all assuming continuous treatment.
• The results assume an ideal scenario where all patients remained on treatment without interruptions, a condition that may not reflect real-world adherence.
• CagriSema is expected to launch early next year, with analysts projecting $11.84 billion in obesity-specific sales by 2028, despite recent investor skepticism.

Background

This news follows recent developments in the GLP-1 market, including Novo Nordisk’s data on the oral Wegovy pill sustaining weight loss and Eli Lilly’s orforglipron showing efficacy across menopausal stages. Novo Nordisk shares had previously dropped 8% after a 2030 growth plan failed to reassure investors regarding competition and patent expiry. The current CagriSema data aims to address concerns about the drug’s differentiation and efficacy compared to existing GLP-1 therapies.

How outlets are covering it

CNBC highlights the potential for CagriSema to outperform Wegovy and notes the specific benefits for women across menopausal stages, while also mentioning Wall Street’s current lack of enthusiasm due to previous trial results. The secondary source, BusinessWorld Online, was inaccessible (404 error) and provided no relevant information on this story. Therefore, the perspective is solely derived from CNBC’s reporting, which balances the promising clinical data with market skepticism and the caveat that the results assume perfect adherence.

Why it matters

The data suggests a potential new standard for weight loss efficacy, particularly for women facing metabolic challenges during menopause. Success for CagriSema could solidify Novo Nordisk’s market position against Eli Lilly and drive significant revenue, while also influencing patient expectations for future obesity treatments. The focus on amylin represents a strategic shift in drug development beyond traditional GLP-1 mechanisms.

What to watch

Novo Nordisk must confirm these hypotheses through further work, as the current data is based on ideal adherence scenarios. The company is expected to launch CagriSema early next year. Investors will watch for how the drug performs in real-world settings and whether it can meet the projected $11.84 billion in sales by 2028, potentially reversing recent market skepticism.